This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
このページの翻訳は実験的なもので、現在 開発中です。お待ちしております!
Albireo Pharma 過去の業績
過去 基準チェック /06
主要情報
-18.1%
収益成長率
-3.0%
EPS成長率
Biotechs 業界の成長 | 17.0% |
収益成長率 | 49.3% |
株主資本利益率 | -131.1% |
ネット・マージン | -228.5% |
前回の決算情報 | 30 Sep 2022 |
最近の業績更新
Recent updates
We're Hopeful That Albireo Pharma (NASDAQ:ALBO) Will Use Its Cash Wisely
Jan 02Rock star Growth Puts Albireo Pharma (NASDAQ:ALBO) In A Position To Use Debt
Oct 25Albireo Pharma achieves positive phase 3 top-line results of Bylvay in Alagille syndrome
Oct 11Albireo Pharma: Assessing The Sagard Deal
Oct 03Albireo gains on royalty agreement for pruritus therapy
Sep 22Albireo gets reimbursed access to liver disease drug Bylvay in Italy
Sep 06These Analysts Just Made A Significant Downgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) EPS Forecasts
Aug 23Albireo Pharma GAAP EPS of -$2.04, revenue of $8.2M
Aug 15Albireo: The Commercialization Of Bylvay Is The Key To A Fair Valuation
Jul 22Despite Lacking Profits Albireo Pharma (NASDAQ:ALBO) Seems To Be On Top Of Its Debt
May 10Albireo: A Speculative Play With Upside
May 03Is Albireo Pharma (NASDAQ:ALBO) Using Debt Sensibly?
Feb 02Albireo: Successful And Accelerating Global Launch Drives Sales Revenue
Jan 31Albireo: Reasons For A Successful Transformation Into A Commercial Company
Nov 24Albireo Pharma: A Post Approval Assessment
Aug 09Albireo reports expanded data on Bylvay and A3907 at EASL international liver congress
Jun 21Some Shareholders May find It Hard To Increase Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Compensation This Year
Jun 11Why Albireo Must Be Valued Higher Than Its Competitor Based On The Value Of Odevixibat
Apr 26Industry Analysts Just Made A Substantial Upgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) Revenue Forecasts
Feb 27Albireo launches late-stage trial of odevixibat in Alagille Syndrome
Dec 17Albireo submits U.S. and European applications for odevixibat in liver disease
Dec 09Albireo Pharma (ALBO) Investor Presentation - Slideshow
Nov 17Albireo Pharma's odevixibat shows durable response in a rare pediatric liver disease
Nov 13収支内訳
収支内訳
Albireo Pharma の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
---|---|---|---|---|
30 Sep 22 | 57 | -131 | 80 | 87 |
30 Jun 22 | 51 | -36 | 77 | 85 |
31 Mar 22 | 45 | -33 | 72 | 83 |
31 Dec 21 | 41 | -34 | 71 | 81 |
30 Sep 21 | 11 | -48 | 65 | 81 |
30 Jun 21 | 9 | -136 | 59 | 82 |
31 Mar 21 | 9 | -120 | 51 | 79 |
31 Dec 20 | 8 | -108 | 44 | 76 |
30 Sep 20 | 12 | -90 | 35 | 70 |
30 Jun 20 | 11 | -82 | 30 | 60 |
31 Mar 20 | 11 | -78 | 27 | 53 |
31 Dec 19 | 10 | -63 | 24 | 45 |
30 Sep 19 | 4 | -71 | 23 | 41 |
30 Jun 19 | 3 | -63 | 21 | 38 |
31 Mar 19 | 2 | -61 | 20 | 34 |
31 Dec 18 | 13 | -46 | 18 | 31 |
30 Sep 18 | 12 | -35 | 17 | 26 |
30 Jun 18 | 12 | -28 | 17 | 19 |
31 Mar 18 | 11 | -19 | 17 | 16 |
31 Dec 17 | 0 | -24 | 16 | 13 |
30 Sep 17 | 3 | -31 | 16 | 10 |
30 Jun 17 | 3 | -28 | 13 | 9 |
31 Mar 17 | 11 | -20 | 12 | 9 |
31 Dec 16 | 11 | -16 | 10 | 8 |
30 Sep 16 | 13 | -5 | 8 | 8 |
30 Jun 16 | 13 | -4 | 8 | 7 |
31 Mar 16 | 5 | -8 | 5 | 6 |
質の高い収益: ALBO is currently unprofitable.
利益率の向上: ALBO is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: ALBO is unprofitable, and losses have increased over the past 5 years at a rate of 18.1% per year.
成長の加速: Unable to compare ALBO's earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: ALBO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.2%).
株主資本利益率
高いROE: ALBO has a negative Return on Equity (-131.05%), as it is currently unprofitable.